Use of FDG PET/CT in identification of bone marrow involvement in diffuse large B cell lymphoma and follicular lymphoma: comparison with iliac crest bone marrow biopsy

Abstract

Background

Non-Hodgkin’s lymphoma (NHL) accounts for around 4% of new cancer cases annually. Bone marrow involvement is important for staging and management. Fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) is used increasingly to identify this, in addition to bone marrow biopsy (BMB), which is seen as “gold” reference standard.

Purpose

To compare determination of bone marrow involvement by FDG PET/CT against BMB in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).

Material and Methods

This was a retrospective study of patients with histologically confirmed NHL at a single UK cancer center undergoing pre-treatment FDG PET/CT and BMB between June 2010 and February 2013. Information was collected from patient notes, cancer registry, histological and imaging reports. Diagnostic accuracy of FDG PET/CT was determined, compared to BMB as the reference standard.

Results

Twenty-four patients with DLBCL and 12 with FL were included. Five DLBCL patients had bone marrow involvement on PET/CT; all were confirmed on BMB. Three FL patients had marrow involvement on PET/CT but not on BMB; one FL patient had positive BMB but negative PET/CT. Using BMB as the reference standard, the sensitivity and specificity of FDG PET/CT for detecting bone marrow involvement in DLBCL were 100% and 100%, respectively, and in FL were 0% and 72.7%, respectively.

Conclusion

FDG PET/CT is accurate for detection of bone marrow involvement in newly diagnosed DLBCL, but not FL. In DLBCL, positive FDG PET/CT may negate the need for routine BMB, although BMB in addition or combination may be appropriate if this would influence management or prognosis.

Keywords

Diffuse large B-cell lymphoma follicular lymphoma bone marrow examination lymphoma non-Hodgkin/radionuclide imaging positron emission tomography (PET)

Get full access to this article

View all access options for this article.

References

Seigel

Zou

et al.

Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9–29.

Pakos

Fotopoulos

Ioannidis

JPA

. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med 2005; 46: 958–963.

Bain

. Morbidity associated with bone marrow aspiration and trephine biopsy. Haematologica 2006; 91: 1293–1294.

Berthet

Cochet

Kanoun

et al.

In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy. J Nucl Med 2013; 54: 1244–1250.

Chen

Jiang

et al.

18F-FDG PET, combined FDG-PET/CT and MRI for evaluation of bone marrow infiltration in staging of lymphoma: a systematic review and meta-analysis. Eur J Radiol 2012; 81: 303–11.

Adams

HJA

Kwee

de Keizer

et al.

FDG PET/CT for the detection of bone marrow involvement in diffuse large B cell lymphoma: systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2014; 41: 565–574.

Tilly

Gomes de Silva

Vitolo

et al.

on behalf of the ESMO guidelines committee. Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Onc 2015; 26: v116–v125.

Adams

HJA

Kwee

. Do not abandon the bone marrow biopsy yet in diffuse large B-cell lymphoma. J Clin Onc 2015; 33: 1217–1217.

Chen

Yeh

Tsui

et al.

F-18 FDG PET for evaluation of bone marrow involvement in non-Hodgkin lymphoma: a meta-analysis. Clin Nucl Med 2011; 36: 553–559.

10.

Lister

Crowther

Sutcliffe

et al.

Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswold meeting. J Clin Oncol 1989; 7: 1630–1636.

11.

Barrington

Mikhaeel

Kostakoglu

et al.

Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol 2014; 32: 3048–3058.

12.

Project

TIN-HsLPF

. A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Factors Project. N Engl J Med 1993; 329: 987–994.

13.

Khan

Barrington

Mikhaeel

et al.

PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement. Blood 2013; 122: 61–67.

14.

Cortes-Romera

Sabate-Llobera

Vilchez

et al.

Bone marrow evaluation in initial staging of lymphoma: 18F-FDG PET/CT versus bone marrow biopsy. Clin Nucl Med 2014; 39: e46–e52.

15.

Hong

Lee

Park

et al.

Role of FDG-PET/CT in detecting lymphomatous bone marrow involvement in patients with newly diagnosed diffuse large B-cell lymphoma. Ann Hematol 2012; 91: 687–695.

16.

Pelosi

Penna

Douroukas

et al.

Bone marrow disease detection with FDG-PET/CT and bone marrow biopsy during the staging of malignant lymphoma: results from a large multicentre study. Q J Nucl Med Mol Imaging 2011; 55: 469–475.

17.

Ribrag

Vanel

Leboulleux

et al.

Prospective study of bone marrow infiltration in aggressive lymphoma by three independent methods: whole-body MRI, PET/ CT and bone marrow biopsy. Eur J Radiol 2008; 66: 325–331.

18.

Wang

Weiss

Chang

et al.

Diagnostic utility of bone marrow examination. Cancer 2002; 94: 1522–1531.

19.

Hopkins

Devenish

Evans

et al.

Subcutaneous seeding of ‘double hit’ diffuse large B-cell lymphoma from staging bone marrow biopsy. Br J Haematol 2014; 166: 635–635.

20.

Adams

de Klerk

Fijnheer

et al.

Bone marrow biopsy in diffuse large B-cell lymphoma: Useful or redundant test?

Acta Oncol 2014; 29: 1–6.

21.

Pelosi

Penna

Deandreis

et al.

FDG-PET in the detection of bone marrow disease in Hodgkin’s disease and aggressive non-Hodgkin’s lymphoma and its impact on clinical management. Q J Nucl Med Mol Imaging 2008; 52: 9–16.

22.

Barrington

Mikhaeel

Kostakoglu

et al.

Reply to B. Bennani-Baiti et al, H.J.A. Adams et al, E. Laffon et al, and E.A. Hawkes et al. J Clin Oncol 2015; 33: 1221–1223.

23.

Le Dortz

De Guibert

Bayat

et al.

Diagnostic and prognostic of 18F-FDG PET/CT in follicular lymphoma. Eur J Nucl Med Mol Imaging 2010; 37: 2307–2314.

24.

Adams

Kwee

Fijnheer

et al.

Utility of quantitative FDG-PET/CT for the detection of bone marrow involvement in follicular lymphoma: a histopathological correlation study. Skeletal Radiol 2014; 43: 1231–1236.

25.

El-Najjar

Montoto

McDowell

et al.

The value of semiquantitative analysis in identifying diffuse bone marrow involvement in follicular lymphoma. Nucl Med Commun 2014; 35: 311–315.

26.

Sovani

Harvey

Haynes

et al.

Bone marrow trephine biopsy involvement by lymphoma: review of histopathological features in 511 specimens and correlation with diagnostic biopsy, aspirate and peripheral blood findings. J Clin Pathol 2014; 67: 389–395.

27.

Arber

George

. Bone marrow biopsy involvement by non-Hodgkin’s lymphoma: frequency of lymphoma types, patterns, blood involvement, and discordance with other sites in 450 specimens. Am J Surg Pathol 2005; 29: 1549–1557.

28.

Adams

HJA

Kwee

Fijnheer

et al.

Bone marrow 18F-fluor-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma. Am J Hematol 2014; 89: 726–731.

29.

Ngeow

Quek

et al.

High SUV uptake on FDG-PET/CT predicts for an aggressive lymphoma in a prospective study of primary FDG-Pet/CT staging in lymphoma. Ann Oncol 2009; 20: 1543–1547.

30.

Dreyling

Ghielmini

Marcus

et al.

Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25: iii76–iii82.

31.

Zelenetz AD, Gordon LI, Wierda WG, et al. NCCN clinic practice guidelines in oncology (NCCN Guidelines): Non-Hodgkin’s Lymphomas. Version 2.2014. National Comprehensive Cancer Network, 2014.